Meihua International Medical Technologies (MHUA) CORRESP Correspondence with SEC

 

VIA EDGAR

February 14, 2022

THE UNITED STATES SECURITIES

AND EXCHANGE COMMISSION

Division of Corporation Finance

Washington, D.C. 20549

Re: Meihua International Medical Technologies Co., Ltd. Amended Registration Statement on Form F-1 File No. 333-258659

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Meihua International Medical Technologies Co., Ltd. (the “Company”) hereby requests acceleration of the effective date of its above-referenced Amended Registration Statement on Form F-1 to 4:00 p.m. Eastern Standard Time on February 15, 2022, or as soon thereafter as is practicable.

The Company acknowledges the following:

● Should the U.S. Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;

● The action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

● The Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Meihua International Medical Technologies Co., Ltd.
By:	/s/ Yulin Wang
	Yulin Wang
	Chief Executive Officer